Macromoltek
Macromoltek provides AI-driven computational antibody design services for biotech and pharmaceutical partners. The platform uses proprietary algorithms and structure modeling to optimize antibody specificity, affinity, and developability, reducing experimental cycles and accelerating therapeutic development from target identification through lead optimization.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Traditional antibody discovery and engineering rely heavily on iterative experimental screening, which is time-consuming, costly, and prone to failure. This slows the development of therapeutic antibodies and increases the risk of clinical attrition, delaying access to precision medicines.
Solution
Macromoltek harnesses computational modeling and artificial intelligence to accelerate and optimize the antibody discovery and engineering process. The platform uses proprietary algorithms to identify and optimize antibodies with high specificity and affinity, streamlining the discovery process and enabling rapid identification of promising therapeutic candidates. Advanced computational modeling tools predict and refine antibody structures, improving accuracy in epitope mapping, developability assessments, and structural optimization, which reduces experimental cycles. From early-stage target identification to lead optimization, the integrated AI-driven platform delivers faster, more accurate candidate selection, reducing time and risk in the drug development pipeline.
Target Audience
Primary customers are biotech and pharmaceutical companies seeking to accelerate therapeutic antibody development and improve clinical success probabilities.
Features
- AI-driven antibody discovery using proprietary algorithms for high specificity and affinity optimization
- Computational structure modeling for antibody structure prediction, epitope mapping, and developability assessments
- Custom antibody engineering partnerships tailored to partner R&D needs, supporting projects from early research to clinical development
- Integrated platform supporting workflows from target identification through lead optimization